In a statement issued on 06/05/2017 Barclays Capital hold steady the price target of Astrazeneca Plc (LON:AZN) from 6,000.00GBX to 6,000.00GBX indicating a possible upside of 0.13%.

Showing a price of 5,322.00GBX, AstraZeneca PLC (LON:AZN) traded -0.02% lower on the day. With the last close up 5.38% from the 200-day moving average, compared to the S&P 500 which has increased 0.03% over the same time period. AZN has recorded a 50-day moving average of 4,885.88GBX and a 200-day moving average of 4,910.79GBX. 2,555,117 shares of the stock were exchanged, up from an average trading volume of 2,517,920

Performance Chart

AstraZeneca PLC has price-earnings ratio of 16.97 with a one year low of 3,996.00GBX and a 52 week high of 5,520.00GBX and has a market capitalization of 0 GBX.

In addition to Barclays Capital reporting its target price, a total of 29 firms have issued a report on AZN. The one year target is 61.96GBX with four analysts rating the company a strong buy, fourteen equity analysts rating the company a buy, thirteen brokerages rating the company a hold, two brokerages rating the stock a underperform, and finally 1 broker rating the stock a sell.

Brief Synopsis On AstraZeneca PLC (LON:AZN)

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

The post Barclays Capital recorded AstraZeneca PLC (LON:AZN), upholding its stock price target at 6,000.00GBX today appeared first on Octafinance.